New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab

   New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel
Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced
  LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High
                                 Cholesterol

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9
Inhibitor, Presented as Featured Clinical Research at ACC.14

Positive Results From the Long-Term Safety and Efficacy Study DESCARTES
Simultaneously Published in the New England Journal of Medicine and the
Monotherapy Study MENDEL-2 Results Simultaneously Published in the Journal of
the American College of Cardiology

Data From Two Additional Phase 3 Studies on Evolocumab to be Presented in
Late-Breaking Session Tomorrow at ACC.14

PR Newswire

THOUSAND OAKS, Calif., March 29, 2014

THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ --Amgen (NASDAQ: AMGN)
today announced new detailed data from three Phase 3 studies that showed
treatment with its novel investigational cholesterol-lowering medication,
evolocumab (AMG 145), resulted in a statistically significant reduction of
55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to
placebo in patients with high cholesterol. Results from the three separate
Phase 3 studies, MENDEL-2, DESCARTES and RUTHERFORD-2, were presented today as
Featured Clinical Research in a Special Session at the American College of
Cardiology's 63^rd Annual Scientific Session (ACC.14). Data from DESCARTES,
the long-term safety and efficacy study, were simultaneously published in the
New England Journal of Medicine and data from MENDEL-2, the monotherapy study,
were simultaneously published in the Journal of the American College of
Cardiology.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/7061854-amgen-at-american-college-of-cardiology-acc-14-march-29

Object: application/x-shockwave-flash

Evolocumab is an investigational fully human monoclonal antibody that inhibits
proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces
the liver's ability to remove LDL-C from the blood.^1

The three Phase 3 studies evaluated evolocumab in different patient
populations: as monotherapy in patients with high cholesterol (MENDEL-2); as a
long-term 52-week therapy in patients with high cholesterol on risk-based
lipid-lowering therapy (DESCARTES); and in combination with statins and other
lipid-lowering therapies in patients with heterozygous familial
hypercholesterolemia (HeFH), a genetic disorder characterized by elevated
LDL-C levels (RUTHERFORD-2).

In MENDEL-2, the most common adverse events (AEs) (≥2 percent in evolocumab
combined group) were headache, diarrhea, nausea and urinary tract infection.
The most common AEs (>5 percent in evolocumab) in the DESCARTES study were
nasopharyngitis, upper respiratory tract infection, influenza and back pain.
In RUTHERFORD-2, the most common AEs (≥2 percent in the combined evolocumab
group) were nasopharyngitis, headache, contusion (i.e., bruise), back pain,
nausea, arthralgia, upper respiratory tract infection, influenza, myalgia and
pain in extremity.

"We are pleased to report positive detailed findings from three of our pivotal
studies in key patient populations at risk for cardiovascular disease," said
Sean E. Harper, M.D., executive vice president of Research and Development at
Amgen. "These results add to the growing body of evidence from our
comprehensive Phase 3 clinical trial program. We look forward to working with
regulatory authorities on our global filing plan in the hopes of bringing this
new treatment option to patients with high cholesterol who have an unmet
medical need."

MENDEL-2, DESCARTES and RUTHERFORD-2 are three of five Phase 3 evolocumab
studies being presented at ACC.14. Data from two other trials, LAPLACE-2 and
GAUSS-2, will be featured in a Late-Breaking Clinical Trials session on
Sunday, March 30, at 8 a.m. EDT.

"Positive results from these first Phase 3 studies provide encouragement that
evolocumab will find use as a treatment for a range of at-risk patients," said
Michael Koren, M.D., clinical investigator for the MENDEL-2 and DESCARTES
studies and the chief executive officer of the Jacksonville Center for
Clinical Research. "The newly released data support the potential of
evolocumab in patients with high cholesterol who struggle to keep their LDL-C
levels under control despite currently available treatments."

MENDEL-2 (Monoclonal Antibody Against PCSK9 to ReduceElevated LDL-C in
Subjects CurrentlyNot ReceivingDrug Therapy forEasingLipid Levels-2)
Primary Results

  oThe MENDEL-2 study showed that in 614 patients with high cholesterol
    (LDL-C ≥100 mg/dL and <190 mg/dL) who were not receiving lipid-lowering
    therapy, treatment with subcutaneous evolocumab significantly reduced mean
    LDL-C by 55-57 percent from baseline compared to placebo and 38-40 percent
    from baseline compared to ezetimibe (p<0.001).

       oResults of the study showed the mean percent reduction from baseline
         in LDL-C at weeks 10 and 12 were 57 percent for evolocumab 140 mg
         every two weeks and 57 percent for evolocumab 420 mg monthly compared
         to placebo; and 39 percent for evolocumab 140 mg every two weeks and
         40 percent for evolocumab 420 mg monthly compared to ezetimibe.
       oAt week 12, the percent reduction from baseline in LDL-C was 57
         percent for evolocumab 140 mg every two weeks and 55 percent for
         evolocumab 420 mg monthly compared to placebo; and 39 percent for
         evolocumab 140 mg every two weeks and 38 percent for evolocumab 420
         mg monthly compared to ezetimibe.

  oThe most common AEs (≥2 percent in evolocumab combined group) were
    headache (3.3 percent evolocumab; 3.2 percent ezetimibe; 2.6 percent
    placebo), diarrhea (2.9 percent evolocumab; 1.9 percent ezetimibe; 3.9
    percent placebo), nausea (2.6 percent evolocumab; 1.9 percent ezetimibe;
    0.6 percent placebo) and urinary tract infection (2.3 percent evolocumab;
    1.9 percent ezetimibe; 1.3 percent placebo).

DESCARTES (DurableEffect of PCSK9 AntibodyCompARed wiTh PlacEboStudy)
Primary Results

  oThe DESCARTES study showed that in 901 patients with high LDL-C and a
    range of cardiovascular risk, evolocumab 420 mg subcutaneous monthly
    reduced mean LDL-C by 57 percent from baseline at week 52 compared to
    placebo (p<0.001).

       oLDL-C reduction for evolocumab at week 12 was consistent with the
         long-term efficacy at week 52.
       oCompared to placebo, the mean percent LDL-C reductions from baseline
         with evolocumab at week 52 are 56 percent, 62 percent, 57 percent and
         49 percent in diet alone, atorvastatin 10 mg, atorvastatin 80 mg, and
         atorvastatin 80 mg plus ezetimibe 10 mg groups, respectively.

  oThe most common AEs (>5 percent in evolocumab) were nasopharyngitis (10.5
    percent evolocumab; 9.6 percent placebo), upper respiratory tract
    infection (9.3 percent evolocumab; 6.3 percent placebo), influenza (7.5
    percent evolocumab; 6.3 percent placebo) and back pain (6.2 percent
    evolocumab; 5.6 percent placebo).

RUTHERFORD-2 (RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous
Familial HyperchOlesteRolemia Disorder Study-2) Primary Results

  oThe RUTHERFORD-2 study showed that in 329 HeFH patients on a stable dose
    of statin and other lipid-lowering therapies, treatment with subcutaneous
    evolocumab significantly reduced mean LDL-C by 59-66 percent from baseline
    compared to placebo (p<0.001).

       oData show the mean percent reduction from baseline in LDL-C at weeks
         10 and 12 were 60 percent for evolocumab 140 mg every two weeks and
         66 percent for evolocumab 420 mg monthly compared to placebo.
       oAt week 12, the percent reduction from baseline in LDL-C was 59
         percent for evolocumab 140 mg every two weeks and 61 percent for
         evolocumab 420 mg monthly compared to placebo.

  oThe most common AEs (≥2 percent in the combined evolocumab group) were
    nasopharyngitis (8.6 percent evolocumab; 4.6 percent placebo), headache
    (4.1 percent evolocumab; 3.7 percent placebo), contusion (i.e., bruise)
    (4.1 percent evolocumab; 0.9 percent placebo), back pain (3.6 percent
    evolocumab; 0.9 percent placebo), nausea (3.6 percent evolocumab; 0.9
    percent placebo), influenza (3.2 percent evolocumab; 0 percent placebo),
    myalgia (2.7 percent evolocumab; 0 percent placebo) and pain in the
    extremity (2.3 percent evolocumab; 2.8 percent placebo).

High cholesterol is the most common form of dyslipidemia, which is an
abnormality of lipids in the blood.^2,3 There are approximately 300 million
cases of dyslipidemia in the U.S., Japan and Western Europe.^4 According to
the Centers for Disease Control and Prevention, more than 71 million American
adults have high LDL-C^5, or "bad" cholesterol, and elevated LDL-C is
recognized as a major risk factor for cardiovascular disease.^6

Patients with familial hypercholesterolemia, an inherited condition that
causes high levels of LDL-C beginning at birth, are at high-risk for
cardiovascular events at an early age.^7 Heterozygous familial
hypercholesterolemia is one of the most common genetic disorders, affecting
approximately one out of every 200 to 500 people worldwide.^8,9

Amgen will also host a webcast investor meeting at ACC.14 on Sunday, March 30,
at 7 p.m. EDT. Sean E. Harper, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's clinical development team
and clinical investigators, will participate at the investor meeting to
discuss Amgen's cardiovascular program, including the primary analyses of five
Phase 3 evolocumab studies being presented at ACC.14.

Live audio of the investor meeting will be simultaneously broadcast over the
Internet and will be available to members of the news media, investors and the
general public.

The webcast, as with other selected presentations regarding developments in
Amgen's business given by management at certain investor and medical
conferences, can be found on Amgen's website, www.amgen.com, under Investors.
Information regarding presentation times, webcast availability and webcast
links are noted on Amgen's Investor Relations Events Calendar. The webcast
will be archived and available for replay for at least 90 days after the
event.

MENDEL-2 Study Design
MENDEL-2 (Monoclonal Antibody Against PCSK9 to ReduceElevated LDL-C in
Subjects CurrentlyNot ReceivingDrug Therapy ForEasingLipid Levels-2) is a
Phase 3 randomized, multicenter, double-blind, double-dummy, placebo- and
ezetimibe-controlled parallel group study designed to evaluate the efficacy
and safety of evolocumab in 614 hyperlipidemic patients with a 10-year
Framingham risk score of 10 percent or less who were not receiving
lipid-lowering therapy. Patients were randomized to one of six treatment
groups to compare two dosing regimens of evolocumab (140 mg every two weeks or
420 mg monthly) with placebo and ezetimibe (10 mg daily). The co-primary
endpoints were the percent reduction from baseline in LDL-C at week 12 and the
mean percent reduction from baseline in LDL-C at weeks 10 and 12.Co-secondary
efficacy endpoints included means at weeks 10 and 12 and at week 12 for the
following: absolute change from baseline in LDL-C; LDL-C <70 mg/dL; and the
percentage change from baseline in non-high-density lipoprotein cholesterol
(non-HDL-C), apolipoprotein B (ApoB), total cholesterol (TC)/HDL-C ratio,
ApoB/apolipoprotein A1 (ApoA1) ratio, lipoprotein(a), triglycerides, HDL-C and
very low-density lipoprotein cholesterol (VLDL-C).

DESCARTES Study Design
DESCARTES (DurableEffect of PCSK9 AntibodyCompARed wiTh PlacEboStudy) is a
Phase 3 randomized, multicenter, double-blind, placebo-controlled study
designed to evaluate the long-term (52-week) safety, tolerability and efficacy
of evolocumab in patients with hyperlipidemia at risk for cardiovascular
disease. Background lipid-lowering therapy was optimized to one of four
treatment groups (diet alone; diet plus atorvastatin 10 mg; diet plus
atorvastatin 80 mg; and diet plus atorvastatin 80 mg plus ezetimibe 10 mg) for
individual patients based on their LDL-C and cardiovascular risk according to
the National Cholesterol Education Program Adult Treatment Panel(NCEP ATP)
III risk categories. After optimization, patients were maintained on therapy
for at least four weeks. A total of 901 patients with a fasting LDL-C ≥75
mg/dL were then randomized and received monthly subcutaneous evolocumab 420 mg
or placebo in combination with background lipid-lowering therapy.

The primary endpoint was percent change from baseline in LDL-C, measured by
the accepted standard, preparative ultracentrifugation, after 52 weeks of
treatment. Secondary efficacy endpoints included the absolute change from
baseline in LDL-C and LDL-C response (LDL-C <70 mg/dL [1.8 mmol/L]) at week
52, percent change from baseline in LDL-C and total cholesterol (TC) at week
12, and percent change from baseline at week 52 in TC, non-high-density
lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), TC/HDL-C ratio,
ApoB/apolipoprotein A1 (ApoA1) ratio, lipoprotein(a), triglycerides, HDL-C and
very low density lipoprotein cholesterol (VLDL-C).

RUTHERFORD-2 Study Design
RUTHERFORD-2 (RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous
Familial HyperchOlesteRolemia Disorder Study-2) is a Phase 3 randomized,
multicenter, double-blind, placebo-controlled trial designed to evaluate the
safety, tolerability and efficacy of evolocumab in 329 patients with HeFH and
an LDL-C ≥100 mg/dL who were on a stable dose of statin therapy and
lipid-lowering medication. Patients were randomized to one of four treatment
groups to compare subcutaneous evolocumab (140 mg every two weeks or 420 mg
monthly) with subcutaneous placebo (every two weeks or monthly). The
co-primary endpoints were the percent reduction from baseline in LDL-C at week
12 and the mean percent reduction from baseline in LDL-C at weeks 10 and 12.
Co-secondary efficacy endpoints included means at weeks 10 and 12 and at week
12 for the following: absolute change from baseline in LDL-C; LDL-C <70 mg/dL;
and the percentage change from baseline in non-high-density lipoprotein
cholesterol (non-HDL-C), apolipoprotein B (ApoB), total cholesterol (TC)/HDL-C
ratio, ApoB/apolipoprotein A1 (ApoA1) ratio, lipoprotein(a), triglycerides,
HDL-C and very low-density lipoprotein cholesterol (VLDL-C).

About Evolocumab
Evolocumab is a fully human monoclonal antibody that inhibits proprotein
convertase subtilisin/kexin type 9 (PCSK9).^1 PCSK9 is a protein that targets
LDL receptors for degradation and thereby reduces the liver's ability to
remove LDL-C, or "bad" cholesterol, from the blood.^10 Evolocumab, being
developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9
from binding to LDL receptors on the liver surface. In the absence of PCSK9,
there are more LDL receptors on the surface of the liver to remove LDL-C from
the blood.^1

About PROFICIO: The Evolocumab Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascular
Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large
and comprehensive clinical trial program evaluating evolocumab in 20 clinical
trials, with a combined planned enrollment of nearly 30,000 patients.

The Phase 3 program includes 14 trials to evaluate evolocumab administered
every two weeks and monthly in multiple patient populations, including in
combination with statins in patients with hyperlipidemia (LAPLACE-2 and
YUKAWA-2); in patients with hyperlipidemia who cannot tolerate statins
(GAUSS-2 and GAUSS-3); as a stand-alone treatment in patients with
hyperlipidemia (MENDEL-2); in patients whose elevated cholesterol is caused by
genetic disorders called heterozygous (RUTHERFORD-2 and TAUSSIG) and
homozygous (TESLA and TAUSSIG) familial hypercholesterolemia; as well as the
administration of evolocumab (THOMAS-1 and THOMAS-2).

Five studies in the evolocumab Phase 3 program will provide long-term safety
and efficacy data. These include FOURIER (Further
CardiovascularOUtcomesResearch with PCSK9Inhibition in Subjects
withElevatedRisk), which will assess whether treatment with evolocumab in
combination with statin therapy compared to placebo and statin therapy reduces
recurrent cardiovascular events in approximately 22,500 patients with
cardiovascular disease; DESCARTES (DurableEffect of PCSK9 AntibodyCompARed
wiTh PlacEbo Study) in patients with hyperlipidemia at risk for cardiovascular
disease; OSLER-2 (Open Label Study of Long TERm Evaluation Against LDL-C
Trial-2) in patients with high cholesterol who completed any of the Phase 3
studies; GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy
as Measured by IntraVascular Ultrasound), which will determine the effect of
evolocumab on coronary atherosclerosis in approximately 950 patients
undergoing cardiac catheterization; and TAUSSIG (Trial Assessing Long Term USe
of PCSK9 Inhibition in Subjects with Genetic LDL Disorders), which will assess
the long-term safety and efficacy of evolocumab on LDL-C in patients with
severe familial hypercholesterolemia.

About Amgen's Commitment to Cardiovascular Disease
Amgen is dedicated to addressing important scientific questions in order to
advance care and improve the lives of patients with cardiovascular disease.
Through its own research and development efforts and innovative partnerships,
Amgen has built a robust cardiology pipeline consisting of several
investigational molecules in an effort to address a number of today's
important unmet patient needs, such as high cholesterol and heart failure.

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in theSecurities and Exchange Commission(SEC) reports filed
byAmgen, includingAmgen'smost recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer
toAmgen'smost recent Forms 10-K, 10-Q and 8-K for additional information on
the uncertainties and risk factors related to our business. Unless otherwise
noted, Amgenis providing this information as ofMarch 29, 2014, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen Inc. and its subsidiaries (which are collectively
referred to as we, or us) project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us and our partners to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and we expect
similar variability in the future. We develop product candidates internally
and through licensing collaborations, partnerships and joint ventures. Product
candidates that are derived from relationships may be subject to disputes
between the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we or
others could identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted by
government investigations, litigation and product liability claims. If we fail
to meet the compliance obligations in the corporate integrity agreement
between us and the U.S. government, we could become subject to significant
sanctions. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development.

In addition, sales of our products (including products of our wholly-owned
subsidiaries) are affected by the reimbursement policies imposed by
third-party payers, including governments, private insurance plans and managed
care providers and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we and our partners routinely obtain patents for products and
technology, the protection of our products offered by patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our or our partners' ability to obtain or
maintain patent protection for our products or product candidates. We cannot
guarantee that we will be able to produce commercially successful products or
maintain the commercial success of our existing products. Our stock price may
be affected by actual or perceived market opportunity, competitive position,
and success or failure of our products or product candidates. Further, the
discovery of significant problems with a product similar to one of our
products that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business and
results of operations. Our efforts to integrate the operations of companies we
have acquired may not be successful.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by theU.S. Food and Drug Administration(FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

CONTACT: Amgen
Wendy Woods Williams, 805-341-5797 (media)
Arvind Sood, 805-447-1060 (investors)

References

1.Amgen Data on File, Investigator Brochure.
2.World Health Organization. Quantifying Selected Major Risks to Health. In:
    The World Health Report 2002 - Reducing Risks, Promoting Healthy Life.
    Chapter 4: Geneva: World.
3.Merck Manuals website.
    http://www.merckmanuals.com/professional/endocrine_and_metabolic_disorders/lipid_disorders/dyslipidemia.html.
    Accessed March 2014.
4.National Institute of Health (2006). Federal Register Volume 74 (250).
    Washington, DC: U.S. Government Printing Office.
    http://www.gpo.gov/fdsys/pkg/FR-2009-12-31/html/E9-31072.htm. Accessed
    March 2014.
5.CDC Morbidity and Mortality Weekly Report. Vital Signs: Prevalence,
    Treatment, and Control of High Levels of Low-Density Lipoprotein
    Cholesterol --- United States, 1999--2002 and 2005-2008. February 4, 2011.
    Available at:
    http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6004a5.htm?s_cid=mm6004a5_w.
    Accessed March 2014.
6.American Heart Association (2012). Why cholesterol matters.
    http://www.heart.org/HEARTORG/Conditions/Cholesterol/WhyCholesterolMatters/Why-Cholesterol-Matters_UCM_001212_Article.jsp.
    Accessed March 2014.
7.National Human Genome Research Institute. Learning About Familial
    Hypercholesterolemia.http://www.genome.gov/25520184. Accessed March 2014.
8.World Health Organization. Familial Hypercholesterolaemia Report 1998.
9.Nordestgaard BG. et al. Familial hypercholesterolaemia is underdiagnosed
    and undertreated in the general population: guidance for clinicians to
    prevent coronary heart disease. Eur Heart J. 2013;34:3478-3490.
10.Abifadel M et al. Nat Genet. 2003;34:154-156.

Object: application/x-shockwave-flash



U.S. Burden of Cardiovascular Disease Infographic



Amgen Logo.



To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/7061854-amgen-at-american-college-of-cardiology-acc-14-march-29

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.